Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance

被引：100

作者：

Sakaguchi K. ^{[1
]}

Takeda K. ^{[2
]}

Maeda M. ^{[3
]}

Ogawa W. ^{[1
]}

Sato T. ^{[4
]}

Okada S. ^{[4
]}

Ohnishi Y. ^{[4
]}

Nakajima H. ^{[5
]}

Kashiwagi A. ^{[6
]}

机构：

[1] Division of Diabetes, Metabolism and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe

[2] Kyoto Industrial Health Association, Kyoto

[3] IHI Harima Hospital, Aioi

[4] Sysmex Corporation, Kobe

[5] Department of Clinical Laboratory, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka

[6] Kusatsu General Hospital, Shiga

来源：

Diabetology International | 2016年 / 7卷 / 1期

关键词：

Glucose area under the curve; Glucose intolerance; Oral glucose tolerance test; Screening;

D O I：

10.1007/s13340-015-0212-4

中图分类号：

学科分类号：

摘要：

HbA1c and fasting plasma glucose (FPG) levels are commonly recognized as diagnostic indices for diabetes and glucose intolerance. However, they are not sufficient for clear detection of glucose intolerance in the early stage unless an oral glucose tolerance test (OGTT) is performed. Moreover, even in case of an OGTT, 2-h postprandial plasma glucose (PG) levels, a criterion for glucose intolerance in OGTTs, may not provide complete information regarding glucose tolerance. Whole glucose excursion after OGTT is considered to represent glucose tolerance well, and the glucose area under the curve (AUC) can be an index of glucose excursion. However, few studies have investigated measurement of the glucose AUC in glucose intolerance screening. In the present study, data from 520 OGTTs were analyzed to define the cutoff value for the glucose AUC for glucose intolerance screening. Our results showed that a cutoff value of 290 mg h/dl for the glucose AUC was highly sensitive and specific (90 and 93 %, respectively) for detecting diabetes, impaired glucose tolerance (IGT), and group at increased risk of diabetes (normal glucose tolerance with 1-h PG levels of ≥180 mg/dl after glucose load) and showed a better concordance rate than the use of HbA1c, FPG, or 2-h PG levels. Moreover, the cutoff value for the glucose AUC calculated using the diagnostic criteria in the OGTT (305 mg h/dl) was consistent with the value determined from OGTT analysis. These data suggest a possibility that glucose intolerance screening using a glucose AUC cutoff value of 290 mg h/dl could be useful. © 2015, The Japan Diabetes Society.

引用

页码：53 / 58

页数：5

共 15 条

[1] The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, pp. 977-986, (1993)
[2] Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin, N Engl J Med, 246, pp. 393-403, (2002)
[3] Sakane N., Sato J., Tsushita K., Tsujii S., Kotani K., Tsuzaki K., Tominaga M., Kawazu S., Sato Y., Usui T., Kamae I., Yoshida T., Kiyohara Y., Sato S., Kuzuya H., Japan Diabetes Prevention Program (JDPP) Research Group, Prevention of type 2 diabetes in a primary healthcare setting: three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance, BMC Public Health, 11, pp. 40-47, (2011)
[4] Kuzuya T., Nakagawa S., Satoh J., Kanazawa Y., Iwamoto Y., Kobayashi M., Nanjo K., Sasaki A., Seino Y., Ito C., Shima K., Nonaka K., Kadowaki T., Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus, Report of the Committee on the classification and diagnostic criteria of diabetes mellitus, Diabetes Res Clin Pract, 55, pp. 65-85, (2002)
[5] Standards Australia, Australian standard glycemic index of food, (2007)
[6] Terra S.G., Somayaji V., Schwartz S., Lewin A.J., Teeter J.G., Dai H., Nguyen T.T., Calle R.A., A dose-ranging study of the DPP-IV inhibitor PF-734200 added to metformin in subjects with type 2 diabetes, Exp Clin Endocrinol Diabetes, 119, pp. 401-407, (2011)
[7] Sosenko J.M., Palmer J.P., Greenbaum C.J., Mahon J., Cowie C., Krischer J.P., Chase H.P., White N.H., Buckingham B., Herold K.C., Cuthbertson D., Skyler J.S., Diabetes Prevention Trial-Type 1 Study Group, Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1, Diabetes Care, 30, pp. 38-42, (2007)
[8] Guidance for standard treatment of diabetes mellitus 2014–2015, Bunkodo, (2014)
[9] Kashiwagi A., Kasuga M., Araki E., Oka Y., Hanafusa T., Ito H., Tominaga M., Oikawa S., Noda M., Kawamura T., Sanke T., Namba M., Hashiramoto M., Sasahara T., Nishio Y., Kuwa K., Ueki K., Takei I., Uemoto M., Murakami N., Yamakado M., Yatomi Y., Ohashi H., International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values, J Diabetes Investig, 3, pp. 39-40, (2012)
[10] Olson D.E., Rhee M.K., Herrick K., Ziemer D.C., Twombly J.G., Phillips L.S., Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria, Diabetes Care, 33, pp. 2184-2189, (2010)

← 1 2 →